Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis
A live, multi-source view of Agios Pharmaceuticals, Inc. (AGIO): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare · Industry: Biotechnology · United States · 539 employees · agios.com
AGIO earnings date
Latest earnings: Q2 2026, published Jul 30, 2026. EPS miss. Read the summary
No earnings report for Agios Pharmaceuticals, Inc. (AGIO) is on the Finnhub calendar through Friday, October 9, 2026.
Source: Finnhub earnings calendar, filtered to RapidTradeView’s universe; times are Eastern. Earnings today · This week
Key statistics · as of 2026-09-16
As of 2026-09-16, Agios Pharmaceuticals, Inc. (AGIO) had a market capitalization of $1.96B (forward -8.3) and a beta of 0.60; the shares traded in a 52-week range of $22.24 – $46.00 (-8.8% over the year).
- Market cap
- $1.96B
- Enterprise value
- $1.37B
- Forward P/E
- -8.3
- Price / book
- 1.91
- EPS (trailing)
- $-6.92
- EPS (forward)
- $-3.95
- Payout ratio
- 0.0%
- 52-week range
- $22.24 – $46.00
- 52-week change
- -8.8%
- Beta
- 0.60
- Average volume
- 1.1M
- Shares outstanding
- 59.7M
- Short % of float
- 12.75%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-22
In RapidTradeView’s 2026-09-22 scan of the US universe, Agios Pharmaceuticals, Inc. (AGIO) last closed at $33.95 (the last completed close before that scan).
Technicals at the scan: RSI 52 (neutral territory), price +1.1% versus its 20-day average, 20-day versus 50-day average spread -2.5%, MACD histogram 0.04.
Sentiment inputs: analyst consensus score 68/100.
Next scheduled company event: in 37 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 1 buy and 0 sells of AGIO; corporate insiders filed 0 buys and 0 sells (1 filer, latest disclosure 2026-09-10). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Gilbert Ray Cisneros, Jr. (1B/0S). Who is trading what
RapidTradeView pick record
AGIO has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Agios Pharmaceuticals, Inc. (AGIO) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell AGIO.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.